Aculys Pharma receives orphan drug designation for a diazepam nasal spray: an antiepileptic drug for epileptic seizures

Tokyo, Japan, November 24, 2023 — Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announced that a diazepam nasal spray (compound development code: NRL-1), an antiepileptic drug currently under development for the treatment of epileptic seizures, has been designated as an orphan drug by the Ministry of Health, Labour […]